Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype
暂无分享,去创建一个
A. Nagler | E. Galun | A. Peled | M. Leiba | H. Wald | K. Beider | M. Abraham | O. Ostrovsky | Hanna Bitner | M. Koren-Michowitz | O. Gutwein | Michal Abraham
[1] Arnon Nagler,et al. Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140 , 2013, Clinical Cancer Research.
[2] Sevinç Şahin,et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma , 2013, Annals of Hematology.
[3] A. Trumpp,et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.
[4] S. Rankin. Chemokines and adult bone marrow stem cells. , 2012, Immunology letters.
[5] H. Dolstra,et al. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. , 2012, Blood.
[6] A. Nagler,et al. Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions , 2012, Clinical & developmental immunology.
[7] R. Kerbel,et al. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. , 2011, Cancer research.
[8] M. Merad,et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche , 2011, The Journal of experimental medicine.
[9] S. Sánchez-Ramón,et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. , 2011, Blood.
[10] G. Pizzolo,et al. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12 , 2010, Molecular Cancer.
[11] A. Mantovani,et al. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.
[12] C. Bokemeyer,et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. , 2010, Experimental hematology.
[13] S. Gordon,et al. Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.
[14] S. Yaccoby. Advances in the understanding of myeloma bone disease and tumour growth , 2010, British journal of haematology.
[15] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[16] H. Vogel,et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.
[17] Charles P. Lin,et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.
[18] M. Dimopoulos,et al. Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma , 2009, Leukemia.
[19] A. Dietz,et al. Tumor‐associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma , 2009, American journal of hematology.
[20] G. Basak,et al. Multiple myeloma bone marrow niche. , 2009, Current pharmaceutical biotechnology.
[21] P. Allavena,et al. Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.
[22] S. Vandenberg,et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.
[23] C. Bokemeyer,et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation , 2008, Haematologica.
[24] D. Ribatti,et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma , 2008, Oncogene.
[25] Kenneth C. Anderson,et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.
[26] Jiasen Cheng,et al. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. , 2007, Blood.
[27] L. Ivashkiv,et al. Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages. , 2007, Human immunology.
[28] W. Dalton,et al. Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma , 2006, Clinical Cancer Research.
[29] G. Roodman,et al. Chemokines in multiple myeloma. , 2006, Experimental hematology.
[30] P. Allavena,et al. Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.
[31] D. Ribatti,et al. Bone marrow angiogenesis in multiple myeloma , 2006, Leukemia.
[32] J. Pollard,et al. Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.
[33] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[34] A. Zannettino,et al. Elevated Serum Levels of Stromal-Derived Factor-1α Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients , 2005 .
[35] M. Tsan,et al. Heat shock protein and innate immunity. , 2004, Cellular & molecular immunology.
[36] P. Allavena,et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. , 2004, Seminars in cancer biology.
[37] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[38] A. Hidalgo,et al. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.
[39] M. Schmid. Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth , 2011 .
[40] D. Chauhan,et al. Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.
[41] G. Roodman. Novel targets for myeloma bone disease. , 2008, Expert opinion on therapeutic targets.
[42] A. Zannettino,et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. , 2005, Cancer research.
[43] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.
[44] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.